News of the expanded indication comes during a showdown between the marketer/manufacturer of the drug, Bristol-Myers Squibb (BMS)/Sanofi-Aventis, and Canadian drug company Apotex, which started ...

This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. The Food and Drug Administration said Friday that it will require a new ...

Generic drug maker Apotex Inc. caught the market by surprise yesterday, launching a cheaper copy of the best-selling, blood thinner Plavix in the United States ahead of a likely patent infringement ...

Bristol-Myers Squibb said generic competition on its biggest drug, Plavix, hamstrung third-quarter earnings, while a federal probe expanded to determine whether an ill-fated deal to protect the Plavix ...

A former senior vice-president at Bristol-Myers Squibb has been charged by the US Department of Justice with lying to federal authorities over a deal struck with rival generics maker Apotex. According ...

Paris-based pharma company Sanofi-Aventis reported a 9% gain in third-quarter net profit, lifted by a strong increase in the sales of vaccines and the blood-thinning drug Plavix, which is no longer ...

Shares in Bristol-Myers Squibb continued to decline on Friday as expectation grew that a generic form of its big-selling antithrombotic Plavix could be on the market in the USA later this year. Shares ...

(CN) - A former senior executive with Bristol-Myers Squibb pleaded guilty Monday to lying to the government about patent litigation involving the company's blockbuster drug Plavix, a blood-thinner.

With our free press under threat and federal funding for public media gone, your support matters more than ever. Help keep the LAist newsroom strong, become a monthly member or increase your support ...

On Monday, Connors ordered Bristol-Myers Squibb Company and three U.S.-based subsidiaries of French pharmaceutical company Sanofi to pay more than $834 million in civil penalties for marketing their ...